Morristown, N.J., September 9, 2016 – A new groundbreaking study on CurcuWIN—a highly bioavailable form of curcumin extract—demonstrates efficacy in a healthy population for improving flow mediated dilation (FMD) at a low dose of 1000mg CurcuWIN. Flow mediated dilation is a measure of endothelial function and a predictor of cardiovascular health.
The study entitled “A Novel Form of Curcumin Improves Endothelial Function in Young, Healthy Individuals: A Double-Blind Placebo-Controlled Study” by Jonathan Oliver, et al., was published in the Journal of Nutrition and Metabolism.
“The inner lining of blood vessels is the endothelium and it plays a critical role in vascular health. The development and progression of cardiovascular disease depends on healthy endothelial function,” said Dr. Jonathan Oliver, PhD, CSCS*D, USAW, Assistant Professor, Texas Christian University. “A major contributor to the development of cardiovascular disease is damage to blood vessels, specifically the vessel wall. When this occurs, the vessel does not respond appropriately. Lifestyle behaviors and nutritional interventions that improve the function of the blood vessels lead to a reduced risk of cardiovascular disease.”
As the study name suggests, FloMeD measured the direct impact of a nutrient using flow mediated dilation on endothelial function and shows that supplementation with CurcuWIN impacts healthy circulation.
Sixty healthy, young adults aged 19 to 29, were enrolled in the randomized, double-blind, placebo-controlled study in which FMD was measured at baseline and after 8-weeks of supplementation with a placebo or either 250 mg or 1,000 mg of CurcuWIN, supplying 50 mg and 200 mg of curcumin, respectively. The study demonstrated that 1,000mg of CurcuWIN resulted in a significant improvement in FMD of approximately 3 percentage points (or 37% increase) compared to placebo.
“What’s really exciting about the FloMeD study is that CurcuWIN may potentially reduce CVD risk by 27-52% because every one percentage point increase in FMD potentially reduces cardiovascular risk by 9-17%,” stated Lynda Doyle, Sr. VP Global Marketing, OmniActive Health Technologies. In a subset population of individuals with baseline FMD < 7% both doses resulted in a significant increase in FMD of 3.3 and 3.6 percentage points, respectively. Lower FMD values are considered a risk for CVD.
“CurcuWIN has been at the forefront of the highly-bioavailable curcumin market with our well-controlled clinical trial – the first study of its kind comparing standard and enhanced curcumin products,” said Doyle. “The study showed up to 46-times higher bioavailability compared to other enhanced forms and standard curcumin. We’re excited to show that this new study further supports how CurcuWIN’s greater bioavailability correlates to efficacy at a lower dose and demonstrates a unique benefit for vascular and heart health. CurcuWIN offers a great alternative to standard curcumin ingredients or when considering a bioavailable curcumin for your formulations.”
For more information, please contact:
Wright On Marketing & Communications
OmniActive Health Technologies (omniactives.com) offers scientifically validated, sustainable, IP-protected, health benefit solutions from natural sources for customers in the dietary supplement and functional food and beverage space. OmniActive’s mission is improving lives through enhancing nutrition—through branded health benefit solutions that consumers demand in top categories such as: Active Wellness & Physical Performance; Metabolic Health and Weight Wellness; Vision, Cognition & Mental Wellness; and Daily Energy & Productivity Performance. Some of our leading brands include Lutemax® 2020 in the eye health market, Capsimax® in the weight management market, CurcuWIN® in the sports nutrition and active lifestyle market and enXtra® and Xtenergy™ in the daily energy categories. Lutemax® and CurcuWIN® are also USP certified and Non-GMO Project Verified. With established production, sales and distribution networks in Asia, Europe, North America and South America, OmniActive is well-positioned to understand the unique needs and regulatory landscape of each market. Currently it has manufacturing plants across India, specifically in Pune, Bengaluru and Hosur, which are FDA GMP compliant. It also maintains head offices in Mumbai, India, as well as Morristown, New Jersey.